MISSOULA, MT, October 10, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at BioJapan (https://jcd-expo.jp/en/).
New immunotherapy drugs and vaccine technologies have shown great promise in the treatment of allergy, cancer, and autoimmunity. Inimmune is focused on advancing a unique pipeline vaccine adjuvants and immunotherapy treatment options to enhance patient health.
“Inimmune has made great progress towards the advancement of novel immunotherapies in areas of critical importance to global health,” said Alan Joslyn, CEO of Inimmune. “We are excited to have Dr. Evans represent Inimmune at BioJapan and provide an update on the groundbreaking and innovative research being conducted at Inimmune.”
Inimmune will have a booth in the Montana Pavillion (Booth D-55) during BioJapan at PACIFICO Yokohama from October 11-13, 2023.
